Kidney disease biotech NephroGenex files for a $47 million IPO


Shutterstock photo

NephroGenex, a clinical-stage biotech developing treatments for kidney disease, filed on Monday with the SEC to raise up to $47 million in an initial public offering. The Research Triangle Park, NC-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol NRX. NephroGenex initially filed confidentially on November 8, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by